Filtered By:
Condition: Heart Valve Disease
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 554 results found since Jan 2013.
Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study
CONCLUSIONS: The PORTICO NG Study demonstrates low rates of adverse events and PVL up to 1 year in patients at high or extreme surgical risk, confirming the safety and efficacy of the Navitor THV system.PMID:36895190 | DOI:10.4244/EIJ-D-22-01108
Source: EuroIntervention - March 10, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Lars Sondergaard Antony S Walton Stephen G Worthley Dave Smith Bassem Chehab Ganesh Manoharan Gerald Yong Francesco Bedogni Nicholas Bates Michael J Reardon Source Type: research
One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry
CONCLUSIONS: Compared with the S3, the S3U transcatheter heart valve was associated with similar 1-year clinical outcomes but reduced rates of mild PVL.PMID:36880333 | DOI:10.4244/EIJ-D-22-01022
Source: EuroIntervention - March 7, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Stefano Cannata Caterina Gandolfo Flavio L Ribichini Nicolas van Mieghem Sergio Buccheri Marco Barbanti Sergio Berti Rui Campante Teles Antonio L Bartorelli Giuseppe Musumeci Tommaso Piva Luis Nombela-Franco Ketty La Spina Tullio Palmerini Rik Adrichem Au Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis
ConclusionOur meta-analysis demonstrated that in patients with AF and BHV, compared with VKAs, using DOACs was associated with reduced stroke and major bleeding events without an increase of all-cause mortality and any bleeding. In the population younger than 75 years old, DOAC might be more effective in preventing cardiogenic stroke.
Source: European Journal of Clinical Pharmacology - February 16, 2023 Category: Drugs & Pharmacology Source Type: research
Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis
AbstractTo compare the efficacy/effectiveness and safety of DOACs versus VKAs in patients with a previously and newly surgically implanted BHV with or without AF. A systematic search on MEDLINE and EMBASE was performed till November 2022. Treatment effects were estimated with relative risk (RR) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed with theI2 statistic. Four randomized controlled trials (RCTs), 2 subgroup analysis from ARISTOTLE and ENGAGE-AF-TIMI 48 and 4 observational studies were included for a total of 5808 patients, 1893 on DOACs and 3915 on VKAs. AF prevalence was 98.28%. In the o...
Source: Internal and Emergency Medicine - February 7, 2023 Category: Emergency Medicine Source Type: research
Perioperative Red Blood Cell Transfusion Is Associated With Adverse Cardiovascular Outcomes in Heart Valve Surgery
CONCLUSIONS: In the analysis of the national cohort, perioperative RBC transfusion during heart valve surgery was associated with adverse cardiovascular outcomes correlated with the volume of RBC transfusion.PMID:36730895 | DOI:10.1213/ANE.0000000000006245
Source: Anesthesia and Analgesia - February 2, 2023 Category: Anesthesiology Authors: Hee Jung Kim Ji Eon Kim Ji Yoon Lee Seung Hyung Lee Jae Seung Jung Ho Sung Son Source Type: research
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research
